Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NR1I3 | Q14994 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29466630 | 1.00 | MEN1 (0.56) | MEN1KMT2ABCHENOTUMNPC1 | |
| SCHEMBL29541811 | 0.87 | NOTUM (0.62) | MEN1KMT2ABCHENOTUMNR1I3 | |
| SCHEMBL2419240 | 0.87 | NOTUM (0.62) | MEN1KMT2ABCHENOTUMNR1I3 | |
| SCHEMBL30122343 | 0.82 | ESR2 (0.52) | MEN1KMT2ABCHENR1I3 | |
| SCHEMBL29479856 | 0.81 | BCHE (0.62) | MEN1KMT2ABCHENOTUMNR1I3 | |
| SCHEMBL3783027 | 0.81 | HSD17B3 (0.40) | KMT2ABCHENR1I3ALDH1A1CYP3A4 | |
| SCHEMBL3787281 | 0.81 | HDAC1 (0.44) | BCHEHSD17B3HDAC1HDAC6 | |
| SCHEMBL3748240 | 0.79 | BCHE (0.43) | BCHEKDM4E | |
| SCHEMBL6199079 | 0.78 | NOTUM (0.72) | MEN1KMT2ANOTUMNPC1MITF | |
| SCHEMBL30122333 | 0.78 | GLA (0.44) | MEN1KMT2ABCHENOTUMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022115439-A1 | KRAS G12C INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2020236940-A1 | KRAS G12C INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2020-11-26 | — | — | WO | disclosed |
| EP-3046906-B1 | ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-3046906-B1 | ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-16 | — | — | EP | disclosed |
| US-9725443-B2 | RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725443-B2 | RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725443-B2 | RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-08 | — | — | US | disclosed |
| US-9663469-B2 | RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663469-B2 | RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663469-B2 | RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-30 | — | — | US | disclosed |
| WO-2015035278-A1 | RORγ MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-12 | — | — | WO | disclosed |
| WO-2012111449-A1 | METHOD FOR PRODUCING AROMATIC COMPOUND HAVING RING STRUCTURE THAT INCLUDES NITROGEN ATOM OR OXYGEN ATOM | 国立大学法人名古屋大学 (JP) | 2012-08-23 | — | — | WO | disclosed |
| US-6555549-B2 | Useful in treating acne, baldness, prostatic cancer and hypertrophy in men and hirsutism in women | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2003-04-29 | — | — | US | disclosed |
| US-6552034-B2 | Cyclization of a silylated butadiene reacted with a 2-oxo-1,2,3,4-tetrahydroquinoline; acne; alopecia; prostatic cancer and hypertrophy; hirsutism in women; skin and glandular disorders; anticarcinogenic agents | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2003-04-22 | — | — | US | disclosed |
| EP-0880520-B1 | BENZO [C]QUINOLIZINE DERIVATIVES, THEIR PREPARATION AND USE AS 5-ALPHA-REDUCTASES INHIBITORS | APPLIED RESEARCH SYSTEMS (AN) | 2003-04-16 | — | — | EP | disclosed |
| US-20010047098-A1 | Benzo[c]quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors | MERCK SERONO SA (CH) | 2001-11-29 | — | — | US | disclosed |
| US-20010044542-A1 | Benzo [c] quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors | MERCK SERONO SA (CH) | 2001-11-22 | — | — | US | disclosed |
| US-6303622-B1 | FOR THERAPY OF ACNE, BALDNESS, PROSTATE CANCER, PROSTATIC HYPERTROPHY; HIRSUTISM | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2001-10-16 | — | — | US | disclosed |
| EP-0880520-A1 | BENZO [C]QUINOLIZINE DERIVATIVES, THEIR PREPARATION AND USE AS 5-ALPHA-REDUCTASES INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997029107-A1 | BENZO[C]QUINOLIZINE DERIVATIVES, THEIR PREPARATION AND USE AS 5α-REDUCTASES INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 1997-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044542-A1 | Benzo [c] quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors | CYP3A5, CYP51A1, CYP2F1 | MEN1 3388/4885KMT2A 2616/4885BCHE 807/4885 |
| US-20010047098-A1 | Benzo[c]quinolizine derivatives, their preparation and use as 5alpha-reductases inhibitors | CYP3A5, CYP51A1, CYP2F1 | MEN1 3388/4885KMT2A 2616/4885BCHE 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.